Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.82 EUR | -5.69% | +2.55% | +3.68% |
Mar. 15 | Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development | MT |
2023 | Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results | MT |
Sales 2021 | 1.93M 2.07M | Sales 2022 | 1.9M 2.03M | Capitalization | 5.1M 5.48M |
---|---|---|---|---|---|
Net income 2021 | 1M 1.07M | Net income 2022 | - 0 | EV / Sales 2021 | 3.77 x |
Net cash position 2021 | 486K 521K | Net cash position 2022 | 421K 452K | EV / Sales 2022 | 2.47 x |
P/E ratio 2021 |
4.78
x | P/E ratio 2022 |
14
x | Employees | 7 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 57.51% |
1 day | -5.69% | ||
1 week | +2.55% | ||
Current month | +2.92% | ||
1 month | +0.71% | ||
3 months | -2.76% | ||
6 months | -6.00% | ||
Current year | +3.68% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 94-12-31 | |
Patrice Coffe
DFI | Director of Finance/CFO | 55 | 08-06-30 |
Chief Tech/Sci/R&D Officer | - | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jean-Luc Rivière
BRD | Director/Board Member | - | 12-06-25 |
Chief Executive Officer | 50 | 94-12-31 | |
Patrice Coffe
DFI | Director of Finance/CFO | 55 | 08-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 2.82 | -5.69% | 46,585 |
24-04-24 | 2.99 | +0.50% | 27,701 |
24-04-23 | 2.975 | +0.85% | 23,157 |
24-04-22 | 2.95 | +1.72% | 8,884 |
24-04-19 | 2.9 | +5.45% | 41,321 |
Real-time Euronext Paris, April 25, 2024 at 11:35 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+3.68% | 10.01M | |
-11.94% | 194B | |
+3.28% | 155B | |
+1.80% | 167B | |
+5.74% | 101B | |
+5.50% | 76.69B | |
+16.72% | 72.08B | |
-6.85% | 71.48B | |
-23.37% | 50.93B | |
+4.06% | 48.89B |
- Stock Market
- Equities
- ALKLA Stock